GNMX Aevi Genomic Medicine, Inc.

1.86
+0  (3%)
Previous Close 1.81
Open 1.85
Price To book 1.92
Market Cap 69.02M
Shares 37,109,000
Volume 771,938
Short Ratio 2.01
Av. Daily Volume 775,589

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2H 2017.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  2. Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  3. Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
  4. GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism
  5. Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine
  6. Why Aevi Genomic Medicine Got Crushed Today
  7. Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
  8. Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
  9. Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  10. Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference
  11. Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia
  12. Aevi Genomic Medicine Announces 2017 Investor Day
  13. Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  14. ($$) Clinical Development News, Jan. 30-Feb. 3
  15. Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
  16. Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
  17. Aevi Genomic Medicine, Inc. :GNMX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016